Goldman Sachs’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-713,821
| Closed | -$9.34M | – | 6462 |
|
|
2025
Q4 | $9.34M | Buy |
713,821
+484,658
| +211% | +$5.79M | ﹤0.01% | 3156 |
|
|
2025
Q3 | $1.67M | Buy |
229,163
+51,851
| +29% | +$351K | ﹤0.01% | 4633 |
|
|
2025
Q2 | $950K | Buy |
177,312
+18,724
| +12% | +$90.8K | ﹤0.01% | 4749 |
|
|
2025
Q1 | $847K | Sell |
158,588
-57,954
| -27% | -$405K | ﹤0.01% | 4820 |
|
|
2024
Q4 | $1.94M | Sell |
216,542
-55,300
| -20% | -$587K | ﹤0.01% | 4306 |
|
|
2024
Q3 | $2.99M | Sell |
271,842
-123,303
| -31% | -$1.37M | ﹤0.01% | 3788 |
|
|
2024
Q2 | $3.6M | Buy |
395,145
+181,611
| +85% | +$1.77M | ﹤0.01% | 3458 |
|
|
2024
Q1 | $3.01M | Buy |
213,534
+197,158
| +1,204% | +$2.46M | ﹤0.01% | 3540 |
|
|
2023
Q4 | $126K | Sell |
16,376
-12,154
| -43% | -$67.2K | ﹤0.01% | 5258 |
|
|
2023
Q3 | $213K | Buy |
28,530
+2,897
| +11% | +$24.7K | ﹤0.01% | 5025 |
|
|
2023
Q2 | $214K | Sell |
25,633
-46,524
| -64% | -$537K | ﹤0.01% | 5155 |
|
|
2023
Q1 | $960K | Buy |
+72,157
| New | +$976K | ﹤0.01% | 4403 |
|
|
2021
Q4 | – | Sell |
-11,221
| Closed | -$99K | – | 6451 |
|
|
2021
Q3 | $99K | Sell |
11,221
-2,232
| -17% | -$21.4K | ﹤0.01% | 5909 |
|
|
2021
Q2 | $170K | Buy |
13,453
+7,621
| +131% | +$99K | ﹤0.01% | 5798 |
|
|
2021
Q1 | $101K | Buy |
5,832
+3,166
| +119% | +$57.2K | ﹤0.01% | 5844 |
|
|
2020
Q4 | $34K | Sell |
2,666
-2,444
| -48% | -$43.6K | ﹤0.01% | 5414 |
|
|
2020
Q3 | $190K | Sell |
5,110
-1,897
| -27% | -$75.2K | ﹤0.01% | 4935 |
|
|
2020
Q2 | $270K | Buy |
+7,007
| New | +$250K | ﹤0.01% | 4673 |
|
|
2018
Q1 | – | Sell |
-273
| Closed | -$24K | – | 5899 |
|
|
2017
Q4 | $24K | Buy |
+273
| New | +$32.1K | ﹤0.01% | 6088 |
|
|
2017
Q2 | – | Sell |
-318
| Closed | -$31K | – | 6756 |
|
|
2017
Q1 | $31K | Buy |
318
+106
| +50% | +$14.6K | ﹤0.01% | 6408 |
|
|
2016
Q4 | $46K | Buy |
+212
| New | +$51.9K | ﹤0.01% | 6402 |
|
|
2016
Q2 | – | Sell |
-185
| Closed | -$56K | – | 7011 |
|
|
2016
Q1 | $56K | Buy |
+185
| New | +$63.8K | ﹤0.01% | 6367 |
|
|
2015
Q3 | – | Sell |
-417
| Closed | -$305K | – | 7266 |
|
|
2015
Q2 | $305K | Buy |
+417
| New | +$315K | ﹤0.01% | 5724 |
|
Goldman Sachs's ATXS Position: Q1 2026 in Review
Goldman Sachs sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 713,821 shares — an estimated $9.34M sold.
Goldman Sachs first reported a position in ATXS in Q2 2015 and held it in 23 quarters. The position peaked at $9.34M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Goldman Sachs reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 713,821 Astria Therapeutics shares in Q1 2026, an estimated $9.34M.
- Goldman Sachs first reported a position in Astria Therapeutics in Q2 2015 and held it in 23 quarters.
- Goldman Sachs's Astria Therapeutics position peaked at $9.34M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.